Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

IDH

2 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.

Clinical

Treatment patterns and outcomes in high-risk WHO grade 2 diffuse glioma: a multicentre retrospective cohort study

Jia JL, Alshamsan B, Andronic C, et al.

Journal of neuro-oncology

This retrospective multicenter Canadian study investigated treatment patterns and outcomes in 116 patients with high-risk WHO grade 2 diffuse glioma, treated with radiotherapy and adjuvant alkylating chemotherapy (temozolomide or PCV). Favorable overall survival and progression-free survival rates were observed, with 5-year rates of 94.1% and 77.9% respectively. IDH mutational status emerged as the dominant independent prognostic factor. While no significant difference in progression-free survival was found between temozolomide and PCV in IDH-mutant patients, PCV was associated with higher hematologic toxicity and more dose modifications.